Drugs / Lispro Mid Mix
last change Nov 2009 re-read 2 minutes ago

Lispro Mid Mix

also known as lispro mix 50/50

Protein / enzyme biologic

Developed for
type 2 diabetes mellitus
Investigated by
Eli Lilly and Company

Trials 1 · a red edge is where a trial was stopped

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT00279201 Dec 2005 → Nov 2009 type 2 diabetes mellitus Eli Lilly and Company Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Lispro Mid Mix ClinicalTrials.gov intervention name — accepted as the source's own label NCT00279201
Known as lispro mix 50/50 “patients previously on lispro mix 75/25 will receive lispro mix 50/50 (50% insulin lispro protamine suspension, 50% lispro) thrice daily or basal/bolus therapy.” PMID 19885269 Sep 2008
Modality Protein / enzyme biologic “insulin lispro protamine suspension” PMID 19885269 Sep 2008
Route Subcutaneous “Lispro Mid Mix subcutaneous injection 3 times daily.” NCT00279201